AbbVie's $10 Billion Acquisition of Immunogen

This chapter discusses AbbVie's acquisition of Immunogen, a biotech company specializing in cancer medicines. The deal includes an FDA approved cancer medicine and showcases the growing potential of antibody drug conjugate (ADC) technology in oncology. The chapter also explores other major deals in the biotech industry involving ADC technology and discusses the challenges and future potential of CAR-T therapy in cancer treatment.